SUTL Enterprise (SGX:BHU) Will Pay A Dividend Of SGD0.05
The board of SUTL Enterprise Limited (SGX:BHU) has announced that it will pay a dividend on the 19th of June, with investors receiving SGD0.05 per share. The dividend yield will be 7.2% based on this payment which is still above the industry average.
We've discovered 2 warning signs about SUTL Enterprise. View them for free.
We like to see robust dividend yields, but that doesn't matter if the payment isn't sustainable. SUTL Enterprise was earning enough to cover the previous dividend, but it was paying out quite a large proportion of its free cash flows. By paying out so much of its cash flows, this could indicate that the company has limited opportunities for investment and growth.
Over the next year, EPS could expand by 27.3% if recent trends continue. If the dividend continues along recent trends, we estimate the payout ratio will be 47%, which is in the range that makes us comfortable with the sustainability of the dividend.
Check out our latest analysis for SUTL Enterprise
SUTL Enterprise's dividend has been pretty stable for a little while now, but we will continue to be cautious until it has been demonstrated for a few more years. The annual payment during the last 8 years was SGD0.02 in 2017, and the most recent fiscal year payment was SGD0.05. This implies that the company grew its distributions at a yearly rate of about 12% over that duration. The dividend has been growing rapidly, however with such a short payment history we can't know for sure if payment can continue to grow over the long term, so caution may be warranted.
The company's investors will be pleased to have been receiving dividend income for some time. It's encouraging to see that SUTL Enterprise has been growing its earnings per share at 27% a year over the past five years. The company doesn't have any problems growing, despite returning a lot of capital to shareholders, which is a very nice combination for a dividend stock to have.
In summary, while it's good to see that the dividend hasn't been cut, we are a bit cautious about SUTL Enterprise's payments, as there could be some issues with sustaining them into the future. While SUTL Enterprise is earning enough to cover the dividend, we are generally unimpressed with its future prospects. We would be a touch cautious of relying on this stock primarily for the dividend income.
Companies possessing a stable dividend policy will likely enjoy greater investor interest than those suffering from a more inconsistent approach. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. To that end, SUTL Enterprise has 2 warning signs (and 1 which is a bit concerning) we think you should know about. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
3 Asian Penny Stocks With Market Caps Below US$800M
As Asian markets navigate the complexities of global trade tensions and economic shifts, investors are increasingly looking for opportunities beyond the major indices. Penny stocks, a term that may seem outdated but remains significant, refer to smaller or newer companies that can offer unique investment opportunities. In this article, we explore three such penny stocks in Asia that stand out for their financial strength and potential for growth, providing investors with a chance to uncover hidden value in lesser-known companies. Name Share Price Market Cap Financial Health Rating Lever Style (SEHK:1346) HK$1.15 HK$725.59M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$1.88 HK$3.25B ★★★★★☆ TK Group (Holdings) (SEHK:2283) HK$2.09 HK$1.74B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.44 SGD178.33M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.20 HK$2B ★★★★★★ Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.31 SGD9.09B ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.176 SGD35.06M ★★★★★★ BRC Asia (SGX:BEC) SGD3.11 SGD853.23M ★★★★★★ Bosideng International Holdings (SEHK:3998) HK$4.38 HK$50.15B ★★★★★★ Click here to see the full list of 1,153 stocks from our Asian Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Scales Corporation Limited is involved in the manufacturing and trading of food ingredients across New Zealand, Asia, Europe, North America, and other international markets, with a market cap of NZ$648.15 million. Operations: The company generates revenue from three main segments: Horticulture (NZ$248.88 million), Global Proteins (NZ$266.79 million), and Logistics (NZ$98.80 million). Market Cap: NZ$648.15M Scales Corporation Limited, with a market cap of NZ$648.15 million, demonstrates strong financial health as its short-term assets cover both short-term and long-term liabilities. The company has achieved significant earnings growth of 486.9% over the past year, surpassing industry averages and improving its net profit margins from 0.9% to 5.3%. Despite this growth, it trades at a substantial discount to its estimated fair value, suggesting potential for appreciation. Debt management is robust with cash flow well covering debt obligations and interest payments comfortably managed by EBIT. Management's experience further supports operational stability without recent shareholder dilution concerns. Click here and access our complete financial health analysis report to understand the dynamics of Scales. Gain insights into Scales' future direction by reviewing our growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Tian Ge Interactive Holdings Limited operates live social video platforms and other services in China and internationally, with a market cap of HK$773.88 million. Operations: The company's revenue primarily comes from its Online Interactive Entertainment segment, which generated CN¥5.64 million. Market Cap: HK$773.88M Tian Ge Interactive Holdings has transitioned to profitability, reporting a net income of CN¥20 million for 2024 compared to a significant loss the previous year. Despite low revenue of CN¥10.16 million, the company's financial performance improved due to increased fair value of financial assets and unlisted equity investments. However, its dividend yield is not well-supported by earnings or cash flow. The company maintains more cash than debt but struggles with negative operating cash flow impacting debt coverage. Recent board changes indicate strategic shifts, with experienced management potentially enhancing governance and operational synergies in the future. Take a closer look at Tian Ge Interactive Holdings' potential here in our financial health report. Explore historical data to track Tian Ge Interactive Holdings' performance over time in our past results report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: China Travel International Investment Hong Kong Limited offers travel and tourism services, with a market capitalization of HK$5.92 billion. Operations: The company's revenue is primarily derived from Tourist Attraction and Related Operations at HK$2.35 billion, Passenger Transportation Operations at HK$1.09 billion, Hotel Operations at HK$820.65 million, and Travel Document and Related Operations at HK$344.02 million. Market Cap: HK$5.92B China Travel International Investment Hong Kong Limited, with a market cap of HK$5.92 billion, primarily generates revenue from tourist attractions and transportation services. Despite having more cash than debt and stable short-term liabilities coverage, the company faces challenges with declining profit margins, which fell to 2.3% from 5.3% last year due to a large one-off loss of HK$223.5 million in 2024. Recent amendments to its Articles of Association aim to modernize operations and improve flexibility in corporate governance, while experienced management oversees strategic adjustments amid negative earnings growth over the past year. Click to explore a detailed breakdown of our findings in China Travel International Investment Hong Kong's financial health report. Assess China Travel International Investment Hong Kong's future earnings estimates with our detailed growth reports. Click through to start exploring the rest of the 1,150 Asian Penny Stocks now. Ready To Venture Into Other Investment Styles? We've found 20 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NZSE:SCL SEHK:1980 and SEHK:308. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Discover China Shengmu Organic Milk And 2 Other Promising Asian Penny Stocks
Amidst a backdrop of fluctuating global trade policies and economic indicators, Asian markets are navigating a complex landscape. Investors seeking opportunities beyond established giants might find value in penny stocks, which often represent smaller or emerging companies. Despite the somewhat outdated terminology, these stocks can still offer surprising value and potential for growth when backed by solid financial foundations. Name Share Price Market Cap Financial Health Rating Lever Style (SEHK:1346) HK$1.15 HK$725.59M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$1.88 HK$3.25B ★★★★★☆ TK Group (Holdings) (SEHK:2283) HK$2.09 HK$1.74B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.44 SGD178.33M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.20 HK$2B ★★★★★★ Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.31 SGD9.09B ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.176 SGD35.06M ★★★★★★ BRC Asia (SGX:BEC) SGD3.11 SGD853.23M ★★★★★★ Bosideng International Holdings (SEHK:3998) HK$4.38 HK$50.15B ★★★★★★ Click here to see the full list of 1,153 stocks from our Asian Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: China Shengmu Organic Milk Limited is an investment holding company that produces and distributes raw milk and dairy products in the People's Republic of China, with a market cap of HK$1.82 billion. Operations: The company generates CN¥3.13 billion in revenue from its dairy farming business segment. Market Cap: HK$1.82B China Shengmu Organic Milk Limited, with a market cap of HK$1.82 billion, faces challenges typical of penny stocks such as volatility and financial instability. The company reported a net loss of CN¥65.5 million for 2024, contrasting with a profit the previous year, and did not declare a dividend. Although its operating cash flow covers 40.3% of its debt and it maintains a satisfactory net debt to equity ratio of 37.4%, short-term liabilities exceed assets by CN¥500 million. Despite these issues, its seasoned management team offers stability amidst the financial struggles common in this investment category. Unlock comprehensive insights into our analysis of China Shengmu Organic Milk stock in this financial health report. Explore historical data to track China Shengmu Organic Milk's performance over time in our past results report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Scholar Education Group is an investment holding company that provides private education services in the People's Republic of China and Hong Kong, with a market cap of HK$2.45 billion. Operations: The company generates revenue primarily from its private education services, amounting to CN¥852.33 million. Market Cap: HK$2.45B Scholar Education Group, with a market cap of HK$2.45 billion, demonstrates financial stability uncommon in penny stocks. The company has high-quality earnings and its revenue is projected to grow by 26.94% annually. Scholar Education's debt is well-covered by operating cash flow and it maintains a strong balance sheet with short-term assets exceeding both short- and long-term liabilities. Recent board changes include the appointment of Prof. Zhang Wenjun, enhancing its experienced management team. The company declared a final dividend of HKD 0.07 per share for 2024, reflecting solid performance and shareholder returns amidst strategic growth initiatives. Get an in-depth perspective on Scholar Education Group's performance by reading our balance sheet health report here. Examine Scholar Education Group's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★★★ Overview: CSE Global Limited is an investment holding company that provides integrated industrial automation, information technology, and intelligent transport solutions across the Asia Pacific, the Americas, Europe, the Middle East, and Africa with a market capitalization of SGD332.09 million. Operations: The company's revenue is derived from three primary segments: Automation (SGD194.36 million), Communications (SGD232.04 million), and Electrification (SGD434.78 million). Market Cap: SGD332.09M CSE Global Limited, with a market cap of SGD332.09 million, offers a compelling profile in the penny stock landscape. The company is trading at 61.7% below its estimated fair value and demonstrates financial prudence with short-term assets exceeding liabilities and satisfactory debt coverage by operating cash flow. Despite low return on equity (10.3%) and declining earnings over five years, recent profit growth of 16.9% shows promise, outpacing industry averages. However, the dividend yield of 5.11% is not well-supported by free cash flows, and recent board retirements could impact governance stability as strategic shifts unfold. Click to explore a detailed breakdown of our findings in CSE Global's financial health report. Explore CSE Global's analyst forecasts in our growth report. Click this link to deep-dive into the 1,153 companies within our Asian Penny Stocks screener. Looking For Alternative Opportunities? AI is about to change healthcare. These 22 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1432 SEHK:1769 and SGX:544. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 days ago
- Yahoo
HighTide Therapeutics And 2 Other Asian Penny Stocks To Watch Closely
Amidst a backdrop of fluctuating global trade policies and easing inflation, Asian markets have been navigating a complex economic landscape. For investors eyeing opportunities in smaller or newer companies, penny stocks—though an outdated term—still hold potential for growth at accessible price points. These stocks can offer notable value when backed by strong financials, making them intriguing options for those seeking hidden gems with promising long-term prospects. Name Share Price Market Cap Financial Health Rating Halcyon Technology (SET:HTECH) THB2.64 THB792M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.445 SGD180.35M ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.176 SGD35.06M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.21 SGD8.7B ★★★★★☆ BRC Asia (SGX:BEC) SGD3.13 SGD858.72M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$1.90 HK$3.28B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.39 HK$50.26B ★★★★★★ Lever Style (SEHK:1346) HK$1.15 HK$725.59M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.20 HK$2B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.04 HK$1.7B ★★★★★★ Click here to see the full list of 1,161 stocks from our Asian Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: HighTide Therapeutics, Inc. is a biopharmaceutical company focused on discovering, researching, developing, and commercializing therapies for metabolic and digestive diseases in Mainland China, with a market cap of HK$1.42 billion. Operations: HighTide Therapeutics, Inc. has not reported any specific revenue segments at this time. Market Cap: HK$1.42B HighTide Therapeutics, Inc., a pre-revenue biopharmaceutical company, recently announced positive Phase 3 trial results for its lead compound HTD1801 in treating type 2 diabetes mellitus. Despite its lack of revenue and current unprofitability, the company has a strong financial position with short-term assets exceeding liabilities and more cash than debt. The management team is experienced, although the board is relatively new. HighTide's stock remains highly volatile, reflecting typical penny stock characteristics. The upcoming NDA submission for HTD1801 could be pivotal if approved by China's regulatory authorities later this year. Take a closer look at HighTide Therapeutics' potential here in our financial health report. Gain insights into HighTide Therapeutics' past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Shandong Molong Petroleum Machinery Company Limited, along with its subsidiaries, focuses on the design, research and development, production, and sale of energy equipment products and services both in China and internationally, with a market cap of HK$3.06 billion. Operations: No specific revenue segments are reported for Shandong Molong Petroleum Machinery Company Limited. Market Cap: HK$3.06B Shandong Molong Petroleum Machinery has shown a mix of financial challenges and operational resilience. Despite being unprofitable, the company maintains a positive cash runway for over three years, supported by CN¥2 billion in short-term assets exceeding its liabilities. However, its high net debt to equity ratio of 201.3% and increased debt levels highlight financial strain. The recent earnings report shows improved revenue but a significant drop in net income compared to the previous year, indicating volatility typical of penny stocks. Management's lack of experience could impact strategic decisions as they navigate these complexities. Unlock comprehensive insights into our analysis of Shandong Molong Petroleum Machinery stock in this financial health report. Assess Shandong Molong Petroleum Machinery's previous results with our detailed historical performance reports. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Chongqing Lummy Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and sale of pharmaceutical products in China with a market cap of CN¥3.92 billion. Operations: The company's revenue is primarily generated from its operations in China, amounting to CN¥812.87 million. Market Cap: CN¥3.92B Chongqing Lummy Pharmaceutical faces financial challenges typical of penny stocks, with a net loss of CN¥13.78 million reported for Q1 2025 despite revenue growth to CN¥198.4 million. The company is unprofitable but has improved its debt profile, reducing the debt-to-equity ratio from 74.9% to 18.6% over five years and maintaining more cash than total debt, providing a stable cash runway exceeding three years even if free cash flow declines. Short-term assets of CN¥1.5 billion comfortably cover liabilities, though ongoing losses necessitate careful management by its experienced leadership team averaging over eight years in tenure. Click to explore a detailed breakdown of our findings in Chongqing Lummy Pharmaceutical's financial health report. Review our historical performance report to gain insights into Chongqing Lummy Pharmaceutical's track record. Click this link to deep-dive into the 1,161 companies within our Asian Penny Stocks screener. Looking For Alternative Opportunities? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2511 SEHK:568 and SZSE:300006. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
